Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Aptinyx To Participate In Cowen Psychedelics & Novel Mechanisms In Neuropsychiatry Summit Jul. 13
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)
Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients
After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ:APTX) has finalized the design of its Phase 2b program for NYX-783…
Aptinyx Says Finalized Design For Phase 2b Program, Says Remains On Track To Commence Q4’21
Finalizes design for Phase 2b program, which remains on track to commence in 4Q 2021
Corrects statistical analysis from previous exploratory Phase 2 study—no impact on study conclusions or future clinical
64 Biggest Movers From Friday
Gainers
Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.
46 Stocks Moving In Friday’s Mid-Day Session
Gainers
Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share.